Compounds > midodrine
Page last updated: 2024-10-31

midodrine and Symptom Cluster

midodrine has been researched along with Symptom Cluster in 6 studies

Midodrine: An ethanolamine derivative that is an adrenergic alpha-1 agonist. It is used as a vasoconstrictor agent in the treatment of HYPOTENSION.
midodrine : An aromatic ether that is 1,4-dimethoxybenzene which is substituted at position 2 by a 2-(glycylamino)-1-hydroxyethyl group. A direct-acting sympathomimetic with selective alpha-adrenergic agonist activity, it is used (generally as its hydrochloride salt) as a peripheral vasoconstrictor in the treatment of certain hypotensive states. The main active moiety is its major metabolite, deglymidodrine.

Research Excerpts

ExcerptRelevanceReference
"We assessed the potency of octreotide and midodrine, and their combination, in the treatment of the postural tachycardia syndrome (POTS) and orthostatic intolerance (OI)."9.12Treatment of postural tachycardia syndrome: a comparison of octreotide and midodrine. ( Bryner, KD; Hobbs, G; Hoeldtke, ME; Hoeldtke, RD, 2006)
"We assessed the potency of octreotide and midodrine, and their combination, in the treatment of the postural tachycardia syndrome (POTS) and orthostatic intolerance (OI)."5.12Treatment of postural tachycardia syndrome: a comparison of octreotide and midodrine. ( Bryner, KD; Hobbs, G; Hoeldtke, ME; Hoeldtke, RD, 2006)

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19901 (16.67)18.7374
1990's0 (0.00)18.2507
2000's4 (66.67)29.6817
2010's1 (16.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Noyes, AM1
Kluger, J1
Honma, K1
Hoeldtke, RD1
Bryner, KD1
Hoeldtke, ME1
Hobbs, G1
Gordon, VM1
Opfer-Gehrking, TL1
Novak, V1
Low, PA1
Samniah, N1
Iskos, D1
Sakaguchi, S1
Lurie, KG1
Benditt, DG1
Sütsch, G1
Vetter, W1
Hess, OM1
Rhyner, K1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Double-Blinded, Placebo-Controlled Study To Assess Hemodynamic Changes, Orthostatic Tolerance, Out-Patient Fatigue And Quality Of Life In Neuropathic And Non-Neuropathic POTS Patients In Response To Adrenoreceptor Agonist And Antagonist[NCT03070730]Phase 1/Phase 28 participants (Actual)Interventional2011-08-15Terminated (stopped due to Recruitment was slow and subjects declined participation after signing the ICF.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Blood Pressure From Baseline

(NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Blood Pressure From Baseline

(NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Blood Pressure From Baseline

(NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline

A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue. (NCT03070730)
Timeframe: 2 weeks after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline

A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue. (NCT03070730)
Timeframe: 2 weeks after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline

A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue. (NCT03070730)
Timeframe: up to 3 days after randomization

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Heart Rate From Baseline

(NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Heart Rate From Baseline

(NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Heart Rate From Baseline

(NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Maximal Postural Tachycardia During Tilt

Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test. (NCT03070730)
Timeframe: Up to 3 days after randomization

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Muscle Sympathetic Nerve Activity From Baseline

(NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Muscle Sympathetic Nerve Activity From Baseline

(NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Muscle Sympathetic Nerve Activity From Baseline

(NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline

"Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better to very much worse." (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline

"Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better to very much worse." (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline

"Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better to very much worse." (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning- HADS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales. (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning- HADS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales. (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning- HADS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales. (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-CIS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS). (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-CIS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS). (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-CIS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS). (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-EuroQOL From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL. (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-EuroQOL From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL. (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-EuroQOL From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL. (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-FSS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale. (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-FSS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale. (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-FSS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale. (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-MFI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI). (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-MFI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI). (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-MFI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI). (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-OI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire. (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-OI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire. (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-OI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire. (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-SF-36 Q From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire. (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-SF-36 Q From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire. (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-SF-36 Q From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire. (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Vascular Resistance From Baseline

(NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Vascular Resistance From Baseline

(NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Vascular Resistance From Baseline

(NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change Maximal Postural Tachycardia During Tilt

Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test. (NCT03070730)
Timeframe: 2 weeks after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change Maximal Postural Tachycardia During Tilt

Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test. (NCT03070730)
Timeframe: 2 weeks after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Reviews

1 review available for midodrine and Symptom Cluster

ArticleYear
[Diabetes mellitus and orthostatic intolerance].
    Nihon rinsho. Japanese journal of clinical medicine, 2005, Volume: 63 Suppl 6

    Topics: Bandages; Diabetic Neuropathies; Diet, Sodium-Restricted; Exercise Therapy; Heart Rate; Humans; Male

2005

Trials

1 trial available for midodrine and Symptom Cluster

ArticleYear
Treatment of postural tachycardia syndrome: a comparison of octreotide and midodrine.
    Clinical autonomic research : official journal of the Clinical Autonomic Research Society, 2006, Volume: 16, Issue:6

    Topics: Adult; Blood Pressure; Data Interpretation, Statistical; Dizziness; Drug Therapy, Combination; Femal

2006

Other Studies

4 other studies available for midodrine and Symptom Cluster

ArticleYear
A tale of two syndromes: Lyme disease preceding postural orthostatic tachycardia syndrome.
    Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc, 2015, Volume: 20, Issue:1

    Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Diet, Gluten-Free; Female; Fluid Therapy; Humans; Lyme Di

2015
Hemodynamic and symptomatic effects of acute interventions on tilt in patients with postural tachycardia syndrome.
    Clinical autonomic research : official journal of the Clinical Autonomic Research Society, 2000, Volume: 10, Issue:1

    Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Antihypertensive Agents; Clonidine; Female; Hemodynamics;

2000
Syncope in pharmacologically unmasked Brugada syndrome: indication for an implantable defibrillator or an unresolved dilemma?
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2001, Volume: 3, Issue:2

    Topics: Adult; Bundle-Branch Block; Defibrillators, Implantable; Diagnosis, Differential; Electrocardiograph

2001
[Dizziness, syncope, orthostatic hypotension].
    Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis, 1988, Nov-29, Volume: 77, Issue:48

    Topics: Aged; Dizziness; Epinephrine; Female; Humans; Hypotension, Orthostatic; Midodrine; Norepinephrine; S

1988